Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Healthcare Biotechnology
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Noxopharm Ltd > Update
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by LMA74on Nov 01, 2012 11:37am
180 Views
Post# 20550038

RE: RE: RE: RE: RE: RE: RE: Update

RE: RE: RE: RE: RE: RE: RE: Update

IR mailed back and Aurizon is delaying phase 3 but will continue soon (when that is I don't know)

The Malartic assays should be today or tomorrow, I have heard that before, let's hope this time they are on time and that they are good.

Management is also talling with several key investors and there should be updated news soon.

I lost with other juniors a lot of money because I selled low and was too impatient, most of them came back and that is really frustating.

This time I am going to wait for  $ 1 + .

I am betting the farm on this one.

Good luck to all longs.

 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities